Compounds > md 230254
Page last updated: 2024-12-10

md 230254

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-(4-(benzyloxy)phenyl)-3-(2-cyanoethyl)-1,3,4-oxadiazol-2(3H)-one: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035812
CHEMBL ID17092
SCHEMBL ID202570
MeSH IDM0216415

Synonyms (18)

Synonym
3-[5-(4-benzyloxy-phenyl)-2-oxo-[1,3,4]oxadiazol-3-yl]-propionitrile
bdbm50029825
md 230254
CHEMBL17092 ,
3-[2-oxo-5-(4-phenylmethoxyphenyl)-1,3,4-oxadiazol-3-yl]propanenitrile
1,3,4-oxadiazole-3(2h)-propanenitrile, 2-oxo-5-(4-(phenylmethoxy)phenyl)-
5-(4-(benzyloxy)phenyl)-3-(2-cyanoethyl)-1,3,4-oxadiazol-2(3h)-one
md-230254
147807-20-3
5-bzph-oxdo
md230254
SCHEMBL202570
5-(4-benzyloxy phenyl) 3-(2-cyano ethyl) 3h-1,3,4-oxadiazole 2-one
RBWUKXWSNXXLOG-UHFFFAOYSA-N ,
DTXSID40163805
5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-2(3h)-one
3-(5-(4-(benzyloxy)phenyl)-2-oxo-1,3,4-oxadiazol-3(2h)-yl)propanenitrile
PD076092
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)0.00510.00040.764912.5000AID102893; AID102894; AID102895; AID102896; AID102897; AID126690; AID1719060; AID1719061
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Ki0.22000.00081.09276.0000AID1719062
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.979812.5000AID102738
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Kieq0.00070.00070.00070.0007AID1719063
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID102579Compound was evaluated for the reversibility test for the percentage inhibition of MAO B at 6.25 nM before the test1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102725Ex-Vivo percentage inhibition of MAO-B after 24 hr single 5 mg/kg dose by oral gavage1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102577Compound was evaluated for the reversibility test for the percentage inhibition of MAO B at 6.25 nM after the test1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102581Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 0.5 hr at single dose 1 mg/kg through oral gavage [p<0.01 (Bonferroni's test)]1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID126690Compound was evaluated for the Inhibition of Monoamine oxidase B1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID102893Compound was evaluated for the time-dependence inhibition of MAO-B at 0 minute pre-incubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102895Compound was evaluated for the time-dependence inhibition of MAO-B at 30 minutes pre-incubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1719063Inhibition of Sprague-Dawley rat brain mitochondrial MAO-B using PEA as substrate preincubated for 60 mins2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.
AID102729Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 4 hr at single dose 5 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102724Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 24 hr at single dose 1500 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1719060Inhibition of Sprague-Dawley rat brain mitochondrial MAO-B using [14C]-PEA as substrate preincubated for 60 mins by radiochemical method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.
AID234048Selectivity for B form was estimated by the ratio of IC50 (MAO A) at 60 min to that of (MAO B)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID234964Selectivity towards MAO A to MAO B1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
AID102727Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 4 hr at single dose 1 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1719062Competitive inhibition of Sprague-Dawley rat brain mitochondrial MAO-B using PEA as substrate by Lineweaver-Burk plot analysis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.
AID102714Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 1 hr at single dose 1 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102723Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 24 hr at single dose 1500 mg/kg through oral gavage1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102896Compound was evaluated for the time-dependence inhibition of MAO-B at 60 minutes preincubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102713Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 0.5 hr at single dose 5 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102718Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 1 hr at single dose 5 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1719061Inhibition of Sprague-Dawley rat brain mitochondrial MAO-B using [14C]-PEA as substrate preincubated for 120 mins by radiochemical method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.
AID102894Compound was evaluated for the time-dependence inhibition of MAO-B at 20 minutes pre-incubation periods1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102897In vitro inhibitory activity on rat brain MAO-B.1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID1719059Selectivity ratio of IC50 for Sprague-Dawley rat brain mitochondrial MAO-A to IC50 for Sprague-Dawley rat brain mitochondrial MAO-B2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.
AID102738Compound was evaluated for the time-dependence inhibition of MAO-A at 60 minutes of preincubated period. values are same with or without pre-incubation1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102722Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 24 hr at single dose 100 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID126365Inhibitory concentration against Monoamine oxidase B was measured in baboon liver.2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Rational approaches towards reversible inhibition of type B monoamine oxidase. Design and evaluation of a novel 5H-Indeno[1,2-c]pyridazin-5-one derivative.
AID102746In Vitro evaluation for the inhibitory activity on rat brain by MAO-A1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102716Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 1 hr at single dose 1500 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102720Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 24 hr at single dose 1 mg/kg through oral gavage (not significant Wilcoxom''s test)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102721Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 24 hr at single dose 100 mg/kg through oral gavage1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID102715Ex-Vivo Time course of evaluation for the percentage inhibition of MAO-B for 1 hr at single dose 100 mg/kg through oral gavage (p<0.001)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
AID234049Selectivity for B form estimated by ratio of IC50 for MAO-A to MAO-B.1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
harmaline
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.		1.9810harmala alkaloidoneirogen
clorgyline
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.. clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.		1.9810aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		2.01101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		2.3920selegiline;
terminal acetylenic compound		geroprotector
lazabemide
lazabemide: structure given in first source		1.9810
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		2.6830
ConditionIndicatedRelationship StrengthStudiesTrials
Dehydration
The condition that results from excessive loss of water from a living organism.		03.2310
Idiopathic Parkinson Disease
[description not available]		03.2310
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		03.2310